Breast cancer anti-hormonal therapy and rheumatic diseases: linking the clinical to molecular world

  • Nadia Melillo | nadiamelillo@yahoo.it Rheumatology Unit, Medical and Surgery Science Department, Riuniti Hospital, Foggia, Italy.
  • Francesco Paolo Cantatore Rheumatology Unit, Medical and Surgery Science Department, Riuniti Hospital, Foggia, Italy.

Abstract

Anti-hormonal therapies are used in the treatment of hormone dependent breast cancer. Their use may be complicated with the onset of arthralgia and autoimmune diseases. Recently a clinical relationship between oestrogen, anti-oestrogen therapy and rheumatic diseases has been reported in the literature, but, until now, experimental supporting data about the interacting biochemical pathways involved are still very limited. The understanding of this molecular link may provide important information to elucidate the relationship between autoimmunity and cancer mechanism and treatment. This review is intended to highlight the relationship between known common molecular mechanisms which explain this association and that probably need to be investigated in future studies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-04-01
Info
Issue
Section
Reviews
Keywords:
Breast cancer, rheumatic diseases, anti-hormonal therapy, aromatase inhibitors.
Statistics
  • Abstract views: 138

  • PDF: 62
How to Cite
Melillo, N., & Cantatore, F. P. (2020). Breast cancer anti-hormonal therapy and rheumatic diseases: linking the clinical to molecular world. Beyond Rheumatology, 2(1), 14-19. https://doi.org/10.4081/br.2020.30